Abstract
The Aotearoa New Zealand Government's recent attempt to ban puberty blockers and the subsequent interim injunction granted by the supreme court has highlighted ethical concerns in the management of gender incongruence and gender dysphoria, particularly when a patient is under the age of 16. The subject of gender-affirming care and the prescription of puberty blockers to young people is a topic not infrequently referred to clinical ethics advisory groups. Despite requests for a National Service, access to clinical ethics advice in Aotearoa New Zealand remains highly variable. This paper provides a clinical ethics approach to the subject with the aim of informing and supporting practitioners and policymakers.